SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Top Headlines

Update

Baxter CMO business to decline 10% after loss of ‘major customer’

Baxter’s contract manufacturing business is expected to take a nearly 10% hit as one of its "major customers" has elected to self-manufacture products previously made by the CMO (contract manufacturing organization), Baxter CFO James Saccaro told investors last week.

Australia looks to speed clinical trial start-up times

Australia’s National Health and Medical Research Council (NHMRC) is getting pragmatic with increasingly long clinical trial timelines and is now looking to streamline the research governance process in order to reduce delays in trial commencement.

TxCell: we’ll continue to use CMO even after we get back our GMP

French biotech TxCell is outsourcing manufacture of its T-cell therapy Ovasave to MaSTherCell, and says it expects to regain GMP certification of its own site later this year.

News in brief

Novartis' Mereo selects Icon as exclusive provider of development services

Mereo BioPharma Group, a recently-formed specialty biopharma company, has selected CRO (contract research organization) Icon as its sole provider of clinical development services. 

China’s FDA calls for verification data on clinical trials

Late last month the China Food and Drug Administration (CFDA) began mandating that drug registration applicants self-inspect and verify clinical data to ensure that it’s authentic and reliable.

Quintiles announces secondary public offering of about $545m worth of stock

CRO Quintiles on Friday announced the pricing of a secondary public offering of 7,000,000 shares of its common stock at a price to the public of $77.85 per share, which is about $1 more per share than what the stock was selling for on Friday. 

Key Industry Events

 

Access all events listing

Our events, Shows & Conferences...